Get to know our clinical trials

Clinical trial of dose escalation and extended dose administration of ISB 2001 as monotherapy in participants with relapsed/refractory multiple myeloma

THE PURPOSE OF THE STUDY IS TO TEST WHETHER AN EXPERIMENTAL DRUG CALLED ISB 2001 IS SAFE AND WELL TOLERATED. THE STUDY WILL ALSO DETERMINE THE DOSE(S) OF ISB 2001 THAT CAN BE SAFELY ADMINISTERED, THE AMOUNT OF THE DRUG THAT ENTERS THE BLOODSTREAM WHILE PARTICIPATING IN THE STUDY, AND WHETHER THE DRUG CAN BE USED TO TREAT MULTIPLE MYELOMA.

Imagen de la Dra. Paula Rodríguez Otero, especialista enHematología de la Clínica Universidad de Navarra. La Dra. Rodríguez se dedica preferencialmente al estudio y tratamiento del mieloma múltiple y el trasplante alogénico.
Dr. Paula Rodríguez Curriculum
Specialist Hematology and Hemotherapy Department
Navarre headquarters
Madrid headquarters
Cancer Center
Hematologic Cancer Area
Status
In recruitment
headquarters
Pamplona
Early phase

Technical Summary

  • PHASE I, FIRST-IN-HUMAN, MULTICENTER, OPEN-LABEL, DOSE-ESCALATION AND DOSE-EXPANSION STUDY OF ISB 2001 MONOTHERAPY IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA
  • Code EudraCT: 2023-507071-21
  • Protocol number: ISB 2001-101
  • Promoter: IGI THERAPEUTICS

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

Imagen de un icono azul con un fonendoscopio o estetoscopio.

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial

I want to make an appointment
Imagen de un icono azul de un registro en el informe médico.

Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.

I WANT TO REQUEST A SECOND OPINION